Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

Core Insights - Genmab A/S announced the presentation of over 20 abstracts, including four oral presentations, at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH), focusing on new clinical data for epcoritamab in treating non-Hodgkin's lymphoma (NHL) patients [1][2][3] Epcoritamab Development Program - The presentations will cover data on fixed-duration subcutaneous epcoritamab in patients with previously untreated diffuse large B-cell lymphoma (DLBCL), large B-cell lymphoma (LBCL), and relapsed/refractory (R/R) follicular lymphoma (FL) [2] - A study evaluating epcoritamab monotherapy in patients with R/R chronic lymphocytic leukemia (CLL) will also be featured [2] - Three-year efficacy and safety data for subcutaneous epcoritamab in patients with R/R DLBCL from the EPCORE NHL-1 trial will be presented [2] Clinical Results and Future Commitments - Dr. Judith Klimovsky highlighted the encouraging clinical results from epcoritamab trials, emphasizing its potential as a core therapy for B-cell malignancies [3] - Genmab, alongside AbbVie, is committed to advancing the epcoritamab development program to provide additional therapeutic options for patients [3] Upcoming Events - Genmab will host a virtual 2024 R&D Update and ASH Data Review on December 11, 2024, to discuss the findings presented at ASH [4] Abstracts and Presentations - Key oral presentations include: - Epcoritamab + R2 in R/R FL with a two-year follow-up from the EPCORE NHL-2 trial [4] - Epcoritamab + R-CHOP in previously untreated DLBCL [4] - Epcoritamab monotherapy in older patients with previously untreated large B-cell lymphoma [4] - Epcoritamab in R/R CLL [4] Research and Development Focus - Genmab and AbbVie are evaluating epcoritamab across various hematologic malignancies, with four ongoing Phase 3 trials [15] - The trials include comparisons of epcoritamab as a monotherapy versus chemotherapy and in combination with other treatments [15] Company Overview - Genmab is an international biotechnology company focused on developing innovative antibody therapeutics, with a vision to transform the lives of patients with cancer by 2030 [16]